Description of position
As a Customer Service, Logistics and S&OP Manager you will
Description of unit
The End-to-end Supply and Planning -unit is part of the Purchasing and Logistics organization within Orion Supply Chain Operations. The main responsibility of the unit is to ensure - in close collaboration with internal and external parties - that the Orion Customers are serviced according to their needs and requirements in a timely and cost-efficient manner. The unit consists of two main functions/teams: Customer service and logistics and Supply chain planning. There are ca. 30 professionals working in the unit, of which ca. 10 in the Customer service and Logistics team.
End-to-end Supply and Planning -unit works in close collaboration with several internal functions, such as production, sales and marketing, QA+QC, purchasing and sourcing, finance, business units, regulatory affairs, product lifecycle management, Orion sales offices, R&D, Fermion and IM. The external collaboration parties consist mainly of Orion B-to-B Customers and logistics service providers.
We offer a very interesting and challenging job, excellent team of true professionals to lead and great colleagues to work with. Independence, accountability, support, trust and lots of opportunities for development - of processes as well as your own personal skills. In Orion we build well-being - together we do work that we are proud of!
We are looking for a positive, energetic and proactive person, who accepts demanding goals and shows drive and determination towards fulfilling them together with his/her team of professionals.
The person should have:
Additional information on the position
Irina Tornikoski, Head of E2E Supply and Planning, tel. 050 966 2056 (available on Monday 23rd July 9.30-10.30, and Monday 6th August 13-14)
Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,085 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki.